Pralatrexate for Prolonged Treatment of Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, with Prophylactic Leucovorin

scientific article published on 01 May 2019

Pralatrexate for Prolonged Treatment of Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, with Prophylactic Leucovorin is …
instance of (P31):
case reportQ2782326
scholarly articleQ13442814

External links are
P356DOI10.1159/000501070
P932PMC publication ID6696769
P698PubMed publication ID31427947

P2093author name stringTakayuki Suzuki
Akira Fujita
Sachie Wada
Koichi Kitazume
Yuri Akagawa
P2860cites workFolotyn (Pralatrexate Injection) for the Treatment of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: U.S. Food and Drug Administration Drug Approval SummaryQ33391588
Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL studyQ33393701
Preemptive leucovorin administration minimizes pralatrexate toxicity without sacrificing efficacyQ33766600
Distribution of malignant lymphoma in Japan: analysis of 2260 cases, 2001-2006.Q34587978
Phase I/II Study of Pralatrexate in Japanese Patients with Relapsed or Refractory Peripheral T-Cell LymphomaQ38644090
Pralatrexate: a comprehensive update on pharmacology, clinical activity and strategies to optimize use.Q39454734
Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivorsQ43609761
Clinico-pathologic features and outcome of Japanese patients with peripheral T-cell lymphomasQ46658608
Recent Advances in the Treatment of Peripheral T-Cell Lymphoma.Q52576595
The outcome of peripheral T-cell lymphoma patients failing first line therapy: a report from the prospective, international T-Cell project.Q52620959
Dismal outcome of T-cell lymphoma patients failing first-line treatment: results of a population-based study from the Modena Cancer RegistryQ87775140
Peripheral T-Cell Lymphomas: Incorporating New Developments in Diagnostics, Prognostication, and Treatment Into Clinical Practice-PART 1: PTCL-NOS, FTCL, AITL, ALCLQ90775432
Clinical Activity of Pralatrexate in Patients With Cutaneous T-Cell Lymphoma Treated With Varying Doses of PralatrexateQ91287640
Strategy for Assessing New Drug Value in Orphan Diseases: An International Case Match Control Analysis of the PROPEL StudyQ92281957
P433issue2
P921main subjectpralatrexateQ637059
peripheral T-cell lymphomaQ7168693
Peripheral T-cell lymphoma not otherwise specifiedQ7168695
P304page(s)529-536
P577publication date2019-05-01
P1433published inCase reports in oncologyQ27722654
P1476titlePralatrexate for Prolonged Treatment of Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, with Prophylactic Leucovorin
P478volume12